Intercept Pharmaceuticals Stock EBITDA
Intercept Pharmaceuticals fundamentals help investors to digest information that contributes to Intercept Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Intercept Stock. The fundamental analysis module provides a way to measure Intercept Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intercept Pharmaceuticals stock.
Intercept |
Intercept Pharmaceuticals Company EBITDA Analysis
Intercept Pharmaceuticals' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Intercept Pharmaceuticals EBITDA | (61.7 M) |
Most of Intercept Pharmaceuticals' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intercept Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, Intercept Pharmaceuticals reported earnings before interest,tax, depreciation and amortization of (61.7 Million). This is 107.03% lower than that of the Biotechnology sector and 161.6% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.58% higher than that of the company.
Intercept EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intercept Pharmaceuticals' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intercept Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Intercept Pharmaceuticals by comparing valuation metrics of similar companies.Intercept Pharmaceuticals is currently under evaluation in ebitda category among its peers.
Intercept Fundamentals
Return On Equity | -0.64 | |||
Return On Asset | -0.0723 | |||
Profit Margin | (0.19) % | |||
Operating Margin | 0.02 % | |||
Current Valuation | 695.84 M | |||
Shares Outstanding | 41.81 M | |||
Shares Owned By Insiders | 3.12 % | |||
Shares Owned By Institutions | 81.30 % | |||
Number Of Shares Shorted | 10.19 M | |||
Price To Earning | (3.88) X | |||
Price To Book | 44.19 X | |||
Price To Sales | 1.60 X | |||
Revenue | 285.71 M | |||
Gross Profit | 284.73 M | |||
EBITDA | (61.7 M) | |||
Net Income | (174.86 M) | |||
Cash And Equivalents | 404.78 M | |||
Cash Per Share | 13.58 X | |||
Total Debt | 332.67 M | |||
Debt To Equity | 411.20 % | |||
Current Ratio | 3.22 X | |||
Book Value Per Share | 1.72 X | |||
Cash Flow From Operations | (26.78 M) | |||
Short Ratio | 2.64 X | |||
Earnings Per Share | (4.26) X | |||
Price To Earnings To Growth | (0.69) X | |||
Target Price | 19.0 | |||
Number Of Employees | 341 | |||
Beta | 0.88 | |||
Market Capitalization | 794.36 M | |||
Total Asset | 553.71 M | |||
Retained Earnings | (2.14 B) | |||
Working Capital | 310.05 M | |||
Current Asset | 641.69 M | |||
Current Liabilities | 47.37 M | |||
Z Score | -3.15 | |||
Net Asset | 553.71 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Other Consideration for investing in Intercept Stock
If you are still planning to invest in Intercept Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intercept Pharmaceuticals' history and understand the potential risks before investing.
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Share Portfolio Track or share privately all of your investments from the convenience of any device |